Santyl

Type: Product
Name: Santyl
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results

By a News Reporter-Staff News Editor at Biotech Week -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced ... [Published HispanicBusiness.com - Mar 12 2014]
First reported Feb 05 2014 - Updated Feb 05 2014 - 1 reports

Smith & Nephew Becomes Pharma Family Factor

NEW YORK (TheStreet) -- Any decent management team will tell you that turning around a struggling business is never easy. If that company happens to be in the realm of medical device technology, case studies are rampant. Companies like Boston Scientific ... [Published The Street Latest - Feb 05 2014]
First reported Jan 23 2014 - Updated Jan 23 2014 - 1 reports

PM360 Announces Winners of 2013 Pharma Choice Awards

The Healthcare Industry Chooses The Top Creative Campaigns of 2013 PM360, a leading health-marketing industry trade magazine, has announced the winners of their annual Pharma Choice Awards, which recognize the best print and digital campaigns in the industry. ... [Published PRWeb - Jan 23 2014]
First reported Oct 31 2013 - Updated Oct 31 2013 - 1 reports

3rd Quarter Results

? Smith & Nephew Q3 Results 31 October 2013 Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces its results for the third quarter ended 28 September 2013. 3 months* to 9 months to 28 Sep 29 Sep Underlying 28 Sep ... [Published TrustNet - Oct 31 2013]

Quotes

"We continued to make progress with pipeline programs in 2013 as well. Within our own pipeline, we reported compelling preclinical data in a new potential indication, uterine fibroids, and plan to report more preclinical data from ongoing studies with Duke Medicine in the second quarter of 2014. Additionally, we reported data from Phase 2 trials in both human and canine lipomas. We are finalizing the full study report from the Chien-804 study and will await Auxilium's decision whether or not to opt-in to the licensing rights for this indication. For the human lipoma indication, we plan to initiate a placebo-controlled trial in the first half of 2014, following positive results reported in January 2014 , which met the primary endpoint of demonstrating efficacy of CCH in reducing the visible surface area of the lipoma. For our partnered indications, Auxilium initiated a Phase 2a trial in cellulite and a Phase 2b trial in frozen shoulder and we can expect top-line data from both studies in the first quarter of 2015."

More Content

All (5) | News (5) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
BioSpecifics Technologies Corp. Reports Fourth ... [Published HispanicBusiness.com - Mar 12 2014]
Smith & Nephew Becomes Pharma Family Factor [Published The Street Latest - Feb 05 2014]
PM360 Announces Winners of 2013 Pharma Choice A... [Published PRWeb - Jan 23 2014]
3rd Quarter Results [Published TrustNet - Oct 31 2013]
Half Yearly Report [Published TrustNet - Aug 01 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.